Sanovel Continues Global Growth Backed by R&D and Domestic Manufacturing Strength

Sanovel, one of Turkey's leading pharmaceutical companies, continues to strengthen its position in global markets through robust R&D infrastructure, domestic production capacity and export-focused growth strategy. The company aims to double its sphere of influence in line with its 2035 vision, while seeking to reduce Turkey's dependence on imported pharmaceuticals through investments in oncology.

Hülya Yalın, Chief Executive Officer of Sanovel, noted that the company has reached a strong structure that exports pharmaceuticals to many countries worldwide, drawing on 43 years of manufacturing experience and the strength it gains from Turkey, and stated that confidence shown by international investors has accelerated this growth journey.

"We grow with the strength we draw from Turkey for 43 years"
Hülya Yalın, recalling that Sanovel was founded in 1983 by pharmacist Erol Toksöz, said the company has become one of the leading establishments in Turkey's pharmaceutical industry today.

Yalın said, "As Sanovel, we grew without compromising our commitment to transparency, quality, science and human-centered approach. We are a Turkish company that draws its strength from Turkey and manages its production, R&D and export operations from our country. We continue our activities at our headquarters in Istanbul Levent and our high-tech R&D and production campus in Silivri. With our team of approximately 2,000 people, we both contribute to our country's health ecosystem and represent Turkey in international markets."

Over 400 licensed products, exports to more than 50 countries
Hülya Yalın, noting that Sanovel has a broad product portfolio consisting entirely of prescription drugs, said the company operates in many therapeutic areas including pain and inflammation, cardiology, neurology, psychiatry, diabetes, gastrointestinal diseases, hematology, hepatology and Multiple Sclerosis (MS).

Yalın continued as follows:

"We have more than 60 brands and over 180 products. Our total number of licensed products exceeds 400. We are proud to be a company that brings to market the first equivalent product in many therapeutic areas. At our Silivri facility, we can manufacture almost all pharmaceutical dosage forms. In addition to Turkey, we confidently deliver pharmaceuticals to more than 50 countries across five continents."

Strong growth in the last 5 years
Noting that Sanovel has gained significant momentum in both production and exports in recent years, Hülya Yalın shared the following information:

According to IQVIA data, growth of 10.5 times on a value basis and 1.5 times on a unit basis was achieved.
Reached a leading position among generic companies in the diabetes field.
Ranked among the top in cardiology and MS treatment areas.
Exports increased approximately 4-fold in the last five years.
Production volume increased from 60 million boxes to 91.5 million boxes.
USD 26 million investment was made in production facilities over the last five years.
Aiming to reduce import dependence through oncology investments

Noting that oncology investments constitute one of the most important aspects of the 2035 vision, Hülya Yalın said they are working on domestic production of oncology drugs that are currently import-dependent.

"We have project teams working in oncology focus. We aim to produce these products, the majority of which are imported, in Turkey, to facilitate patients' access to medicines and to contribute to the protection of our country's foreign exchange resources. Within the scope of our 2035 vision, we aim to double our sphere of influence, rank among the top 10 companies in the Turkish pharmaceutical market and move the Sanovel brand to a stronger position on a global scale." she said.

Operations in 50 countries, growth target in new markets
Noting that Sanovel currently operates in more than 50 countries with over 400 licenses, Yalın stated that they continue to grow in many regulated markets, particularly the European Union, the United States and Canada.

"With our manufacturing facility that holds EMA and European Union GMP certificates as well as US FDA approval, we manufacture products to international quality standards. We currently have over 200 license applications pending completion in various countries. We are focused on growth in Europe, North America, MENA, Sub-Saharan Africa, Southeast Asia, Latin America and the CIS region." he said.

R&D investments continue at pace
Noting that Sanovel continues its work with an R&D team of approximately 80 scientists, Hülya Yalın said innovative projects are being carried out at the R&D center with the goal of developing first-equivalent drugs.

"We are working on combination products, new dosage forms and orally disintegrating tablet technologies. We conduct all our processes in accordance with international quality standards, and with our strong performance in intellectual property, we rank among the top in patent applications in Turkey." she said.

Sustainability and human-focused growth
Expressing that Sanovel places sustainability at the center of all its activities, Hülya Yalın noted that the company continues its work in accordance with the United Nations Global Compact and the Sustainable Development Goals.

Noting that they achieved a 14.3 percent reduction in carbon footprint and a 13.9 percent reduction in water footprint in 2025, Yalın also said they provided professional coaching support to 102 female students, earned the Equal Opportunity Model Certificate and were included in the "Turkey's Best Employers 2026" list prepared by Forbes Turkey and Statista.

"Sanovel is one of Turkey's national values"
Addressing claims that have occasionally been raised about the company, Hülya Yalın emphasized that Sanovel continues its activities with the same determination based in Turkey.

"Sanovel is a Turkish company and is building its future in Turkey. The interest shown by international investors in the company is a reflection of confidence in both the Turkish economy and the potential of our pharmaceutical industry. These strategic investments will take our production capacity, R&D strength, exports and global competitiveness even further." she said.

About Sanovel
Founded in 1983 by pharmacist Erol Toksöz, Sanovel is one of the leading companies in Turkey's pharmaceutical sector. Operating with a portfolio of more than 60 brands, over 180 products and over 400 licensed products, the company has an annual production capacity of 200 million boxes. Sanovel delivers products developed in its European Union cGMP and US FDA-approved manufacturing facilities to more than 50 countries across five continents, continuing to add value to Turkey's pharmaceutical industry through robust R&D infrastructure and export-focused growth strategy.